[논문]Anaplasma marginale inactivated vaccine: dose titration against a homologous challenge

Rodrı́; guez, S.D; Garcı́; a Ortiz, M.A; Herná; ndez Salgado, G; Santos Cerda, N.A; Aboytes Torres, R; Cantó; Alarcó; n, G.J

doi:10.1016/s0147-9571(99)00076-4

Anaplasma marginale inactivated vaccine: dose titration against a homologous challenge

Comparative immunology, microbiology and infectious diseases, v.23 no.4, 2000년, pp.239 - 252

Rodrı́guez, S.D (Centro Nacional de Investigaciones Disciplinarias en Parasitologı́) , Garcı́a Ortiz, M.A (a Veterinaria, INIFAP, SAGAR, Mexico) , Hernández Salgado, G (Centro Nacional de Investigaciones Disciplinarias en Parasitologı́) , Santos Cerda, N.A (a Veterinaria, INIFAP, SAGAR, Mexico) , Aboytes Torres, R (Centro Nacional de Investigaciones Disciplinarias en Parasitologı́) , Cantó (a Veterinaria, INIFAP, SAGAR, Mexico) , Alarcón, G.J (Facultad de Ciencias Naturales, Universidad Autó)

Abstract ▼ AI-Helper

AbstractThe present study was performed to dose-titrate an Anaplasma marginale experimental immunogen derived from partially purified initial bodies from three geographically different Mexican strains. Three five-bovine groups were inoculated twice on days zero and 21 with A. marginale initial bodies equivalent to 1.5×1010 (group I), 3×1010 (group II) or 6×1010 (group III) infected erythrocytes mixed with STDCM® adjuvant. A similar group served as non-vaccinated controls. All four groups were challenged with 1×108 infected erythrocytes from a donor cow with an increasing rickettsemia of strain MEX-15 on day 87 post-vaccination. The prepatent period was very similar for all four groups. All five non-vaccinated controls presented typical acute anaplasmosis syndrome reaching a mean of 30.9% rickettsemia and a loss of 73.4% in the packed cell volume (PCV). Two of five controls died of acute anaplasmosis. Within the vaccinated groups only one animal (group II) suffered acute disease and died. Although all the other vaccinated animals were free of clinical signs, they developed very low rickettsemias (3.2, 3.8 and 4.3%) and PCV losses of 49.9, 47.8, and 49.3% for groups I, II and III. The starting mean weight was very similar for all four groups. All animals lost weight following challenge but losses for groups I and II were lower and significantly different from group IV losses (P⩽0.1). Although there were no significant differences among vaccinated groups, group III was more severely affected. Taken altogether, these results show a 93.3% protection against both illness and death for all groups; and 100% protection for groups I and III, and 80% for group II.

Abstract

RésuméLe but de l’étude était de définir la meilleure dose d’un immunogen expérimental contre l’Anaplasmose bovine. L’immunogen était dérivé des corps initiaux de trois isolats mexicains géographiquement différents. Trois groupes de cinq bovins ont été inoculés deux fois, les jours zéro et vingt et un, avec des corps initiaux équivalents à 1.5×1010 (groupe I), 3×1010 (groupe II) et 6×1010 (groupe III) érythrocytes infectés et mélangés avec l’adjuvant STDCM®. Un groupe semblable de cinq bovins a servi de témoin non vaccinés. Le jour quatre-vingt-sept, les quatre groupes ont été éprouvés avec une dose de 1×108 érythrocytes infectés à l’aide de la souche MEX-15-099-01 d’A. marginale. La période avant l’épreuve était très semblable pour chacun des quatre groupes. Les cinq bovins témoins ont présentés un syndrôme aigu typique d’Anaplasmose atteignant une rickettsemie moyen de 30.9% et une perte de 73.4% de volume cellulaire agglomér, deux d’entre eux sont morts. Parmi les bovins des groupes vaccinés, seul un d’entre eux (groupe II) a présenté un tableau clinique aigu et il est mort. Par ailleurs, aucun des autres animaux vaccinés a présenté de signe clinique, ils ont présenté des rickettsémies très basses (3.2, 3.8, et 4.3%) et des pertes de PCV de 49.9, 47.8 et 49.3% respectivement. Les poids de départ étaient très semblables parmi les quatre groupes avant l’épreuve, après celle-ci, tous les animaux ont perdu poids, cependant les pertes pour les groupes I et II ont été moindre en comparaison avec celles du groupe IV (P<0.01). Bien qu’il n’y ait eu aucune différence significative parmi les groupes vaccinés, le groupe III était légèrement plus affecté. Globalement, ces résultats montrent une protection totale de 93.3% par groupe, 100% pour les groupes I et III et de 80% pour le groupe II.

주제어

참고문헌 (41)

Vet. Mex. UNAM Osorno 8 85 1977 Anaplasmosis bovina, con énfasis en control, diagnóstico, distribución de la enfermedad en México y uso de la vacuna atenuada de A. marginale
Aust. Vet. J. Rogers 65 285 1988 10.1111/j.1751-0813.1988.tb16144.x Bovine leucosis virus contamination of a vaccine produced in vivo against bovine babesiosis and anaplasmosis

상세보기
Am. J. Vet. Res. Corrier 41 1062 1980 Comparison of three methods of immunization against bovine anaplasmosis: an examination of postvaccinal effects

상세보기
J. Am. Vet. Med. Assoc. Henry 183 66 1983 Effects and use of a modified live Anaplasma marginale vaccine in beef heifers in California
Aust. Vet. J. Jorgensen 70 192 1993 10.1111/j.1751-0813.1993.tb06133.x Sheep-adapted Anaplasma marginale maintains virulence for cattle

상세보기
Am. J. Vet. Res. Osorno 36 631 1975 Study of an attenuated Anaplasma marginale vaccine in Mexico - Natural challenge of immunity in enzootic area
Tec. Pecu. Mex. Rodrı́guez 37 1 1 1999 Ensayo de una vacuna experimental inactivada contra Anaplasma marginale
Am. J. Vet. Res. Vizcaino 41 1066 1980 Comparison of three methods of immunization against bovine anaplasmosis: evaluation of protection afforded against field challenge exposure

상세보기
Trop. Anim. Hlth. Prod. Zaraza 3 77 1971 10.1007/BF02356479 Comparative efficacy of different immunization systems against anaplasmosis

상세보기
Trop. Anim. Health. Prod. Anziani 19 83 1987 10.1007/BF02297324 Vaccination with Anaplasma centrale: response after an experimental challenge with Anaplasma marginale

상세보기
Trop. Anim. Hlth. Prod. Pipano 29 4 Suppl 86S 1997 10.1007/BF02632940 Vaccines against hemoparasitic diseases in Israel with special reference to quality assurance

상세보기
Br. Vet. J. Pipano 142 553 1986 10.1016/0007-1935(86)90113-2 Frozen Anaplasma centrale vaccine against anaplasmosis in cattle

상세보기
Br. Vet. J. Pipano 141 174 1985 10.1016/0007-1935(85)90148-4 Comparative response of Frisian milking cows and calves to Anaplasma centrale vaccine

상세보기
J. Vet. Res. Potgieter 50 29 1983 Infectivity, virulence and immunogenicity of Anaplasma centrale live blood vaccine. Onderstepoort
79 1995 Memoria de la IV Reunión Anual. 14-17 de nov. México D.F. Análisis de la situación de las vacunas contra anaplasmosis y babesiosis. Conclusiones y recomendaciones presentadas por el Comité de enfermedades parasitarias
Louisiana Agriculture Hart 31 3 1987 Progress toward an improved vaccine for anaplasmosis
Luther 559 1989 Proceedings of Eighth National Veterinary Hemoparasite Disease Conference, St Louis, MO Field studies of an experimental anaplasmosis vaccine on pregnant cows and neonatal isoerythrolysis
Parasitol. Res. Montenegro 77 93 1991 10.1007/BF00935421 Efficacy of purified Anaplasma marginale initial bodies as vaccine against anaplasmosis

상세보기
Palmer 2 1989 Veterinary and Hemoparasite Vaccines Anaplasma vaccines
Infect. Immun. Palmer 57 3666 1989 10.1128/IAI.57.11.3666-3669.1989 Immunization of cattle with the MSP-1 surface protein complex induces protection against a structurally variant Anaplasma marginale isolate

상세보기
Science Palmer 231 4743 1299 1986 10.1126/science.3945825 Immunization with an isolate-common surface protein protects cattle against anaplasmosis

상세보기
Infect. Immun. Palmer 56 1526 1988 10.1128/IAI.56.6.1526-1531.1988 Immunization of cattle with a 36-kilodalton surface protein induces protection against homologous and heterologous Anaplasma marginale challenge

상세보기
Trop. Anim. Hlth. Prod. Tebele 23 197 1991 10.1007/BF02357100 Crossprotective immunity between the Florida and a Zimbabwe stock of Anaplasma marginale

상세보기
Infect. Immun. McGuire 45 697 1984 10.1128/IAI.45.3.697-700.1984 Common and isolate-restricted antigens of Anaplasma marginale detected with monoclonal antibodies

상세보기
Infect. Immun. Oberle 56 1567 1988 10.1128/IAI.56.6.1567-1573.1988 Molecular size variations in an immunoprotective complex among isolates of Anaplasma marginale

상세보기
Int. J. Parasitol. Palmer 18 33 1988 10.1016/0020-7519(88)90033-1 Recognition of conserved surface protein epitopes on Anaplasma marginale isolates from Israel, Kenya and the United States

상세보기
J. Am. Vet. Med. Assoc. Dennis 156 1861 1970 Neonatal immunohemolytic anemia and icterus of calves

상세보기
CONASA, Experiencias sobre el uso de vacunas contra Anaplasma marginale, Memoria de la IV Reunión Anual. 14-17 de nov. Méico D.F. 1995;79-81
Tec. Pecu. Mex. Garcı́a-Ortiz 36 3 197 1998 Caracterización de la virulencia de un aislado mexicano de Anaplasma marginale
J. Immunol. Palmer 133 1010 1984 10.4049/jimmunol.133.2.1010 Immune serum against Anaplasma marginale initial bodies neutralizes infectivity for cattle

상세보기
Am. J. Vet. Res. Amerault 28 1067 1967 Preparation and characterization of a soluble Anaplasma marginale antigen

상세보기
J. Clin. Microbiol. Winkler 25 633 1987 10.1128/JCM.25.4.633-636.1987 Detection of antibodies to Anaplasma marginale by an improved enzyme-linked immunosorbent assay with sodium dodecyl sulfate-disrupted antigen

상세보기
Snedecor 215 1980 Statistical Methods
Trop. Anim. Hlth. Prod. McHardy 5 166 1973 10.1007/BF02251385 Attempts at immunizing cattle against anaplasmosis using killed vaccine

상세보기
Vet. Immunol. Immunopathol. Brown 63 45 1998 10.1016/S0165-2427(98)00081-6 Bovine type 1 and type 2 responses

상세보기
Infect. Immun. Brown 66 5406 1998 10.1128/IAI.66.11.5406-5413.1998 CD4(+) T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge

상세보기
Immunology McGuire 38 249 1979 Functional properties of bovine IgG1 and IgG2: interactions with complement, macrophages, neutrophils and skin
Am. J. Vet. Res. Budden 38 633 1977 Finite purification of Anaplasma marginale: serologic inactivity of the anaplasma body

상세보기
Am. J. Vet. Res. Kuttler 45 2223 1984 Serologic and clinical responses of premunized, vaccinated, and previously infected cattle to challenge exposure by two different Anaplasma marginale isolates

상세보기
Am. J. Vet. Res. Vizcaino 39 229 1978 Efficacy of attenuated Anaplasma marginale vaccine under laboratory and field conditions in Colombia

상세보기
Infect. Immun. Brown 66 5414 1998 10.1128/IAI.66.11.5414-5422.1998 The repertoire of Anaplasma marginale antigens recognized by CD4(+) T-lymphocyte clones from protectively immunized cattle is diverse and includes major surface protein 2 (MSP-2) and MSP-3

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Anaplasma marginale inactivated vaccine: dose titration against a homologous challenge

Abstract ▼ AI-Helper

Abstract

주제어

참고문헌 (41)

이 논문을 인용한 문헌

관련 콘텐츠

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트